Dr. Reddy's Laboratories announces the launch of Bortezomib for Injection, 3.5 mg Single-Dose Vial in the U.S. Market
July 27 2022 - 3:26AM
Business Wire
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:
RDY, NSEIFSC: DRREDDY, along with its subsidiaries together
referred to as “Dr. Reddy’s”) today announced the launch of
Bortezomib for Injection 3.5 mg, the generic equivalent of Velcade®
(bortezomib) Injection, in the U.S. market approved by the U.S.
Food and Drug Administration (USFDA).
The Velcade® Brand and generic had U.S. sales of approximately
$1.2 billion MAT for the most recent twelve months ending in May
2022 according to IQVIA Health*.
Dr. Reddy’s Bortezomib for Injection is supplied in a 3.5 mg per
10 mL single-dose vial presentation for subcutaneous (SQ) or
intravenous (IV) use.
Click here for full prescribing information:
https://www.drreddys.com/pi/dr-reddy-bortezomib-3.5mg-iv-sc-vial-leaflet.pdf
Velcade is a trademark of Takeda Pharmaceuticals U.S.A.,
Inc.
*IQVIA Retail and Non-Retail MAT May 2022
RDY-0722-430
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE:
500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated
pharmaceutical company, committed to providing affordable and
innovative medicines for healthier lives. Dr. Reddy’s offers a
portfolio of products and services including APIs, custom
pharmaceutical services, generics, biosimilars and differentiated
formulations. Our major therapeutic areas of focus are
gastrointestinal, cardiovascular, diabetology, oncology, pain
management and dermatology. Dr. Reddy’s operates in markets across
the globe. Our major markets include – USA, India, Russia & CIS
countries, and Europe. For more information, log on to:
www.drreddys.com
Disclaimer: This press release may include statements of future
expectations and other forward-looking statements that are based on
the management’s current views and assumptions and involve known or
unknown risks and uncertainties that could cause actual results,
performance or events to differ materially from those expressed or
implied in such statements. In addition to statements which are
forward-looking by reason of context, the words "may", "will",
"should", "expects", "plans", "intends", "anticipates", "believes",
"estimates", "predicts", "potential", or "continue" and similar
expressions identify forward-looking statements. Actual results,
performance or events may differ materially from those in such
statements due to without limitation, (i) general economic
conditions such as performance of financial markets, credit
defaults, currency exchange rates, interest rates, persistency
levels and frequency / severity of insured loss events, (ii)
mortality and morbidity levels and trends, (iii) changing levels of
competition and general competitive factors, (iv) changes in laws
and regulations and in the policies of central banks and/or
governments, (v) the impact of acquisitions or reorganization,
including related integration issues, and (vi) the susceptibility
of our industry and the markets addressed by our, and our
customers’, products and services to economic downturns as a result
of natural disasters, epidemics, pandemics or other widespread
illness, including coronavirus (or COVID-19), and (vii) other risks
and uncertainties identified in our public filings with the
Securities and Exchange Commission, including those listed under
the "Risk Factors" and "Forward-Looking Statements" sections of our
Annual Report on Form 20-F for the year ended March 31, 2022. The
company assumes no obligation to update any information contained
herein.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220727005417/en/
INVESTOR RELATIONS AMIT AGARWAL amita@drreddys.com
MEDIA RELATIONS USHA IYER USHAIYER@DRREDDYS.COM
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Apr 2023 to Apr 2024